Skip to main content

Phase 3, Open-Label, Randomized, Two-Part Study Comparing Gedatolisib in Combination with Palbociclib and Fulvestrant to Standard-of-Care Therapies in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Celcuity

Start Date

December 20, 2022

End Date

December 31, 2029
 

Administered By

Duke Cancer Institute

Awarded By

Celcuity

Start Date

December 20, 2022

End Date

December 31, 2029